NO20013675D0 - 2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer - Google Patents
2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorerInfo
- Publication number
- NO20013675D0 NO20013675D0 NO20013675A NO20013675A NO20013675D0 NO 20013675 D0 NO20013675 D0 NO 20013675D0 NO 20013675 A NO20013675 A NO 20013675A NO 20013675 A NO20013675 A NO 20013675A NO 20013675 D0 NO20013675 D0 NO 20013675D0
- Authority
- NO
- Norway
- Prior art keywords
- benzodiazepine
- tetrahydro
- hydroxamic acid
- matrix metalloproteinase
- metalloproteinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908099A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/001991 WO2000044730A1 (en) | 1999-01-27 | 2000-01-27 | 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20013675D0 true NO20013675D0 (no) | 2001-07-26 |
| NO20013675L NO20013675L (no) | 2001-09-21 |
Family
ID=22900512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013675A NO20013675L (no) | 1999-01-27 | 2001-07-26 | 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1147095B1 (no) |
| JP (1) | JP2002535392A (no) |
| KR (1) | KR20010101730A (no) |
| CN (1) | CN1197849C (no) |
| AR (1) | AR022423A1 (no) |
| AT (1) | ATE273288T1 (no) |
| AU (1) | AU767039B2 (no) |
| BG (1) | BG105736A (no) |
| BR (1) | BR0007759A (no) |
| CA (1) | CA2356267A1 (no) |
| CZ (1) | CZ20012637A3 (no) |
| DE (1) | DE60012883T2 (no) |
| EA (1) | EA200100809A1 (no) |
| ES (1) | ES2223470T3 (no) |
| HU (1) | HUP0105302A3 (no) |
| ID (1) | ID29046A (no) |
| IL (1) | IL144168A0 (no) |
| NO (1) | NO20013675L (no) |
| NZ (1) | NZ511885A (no) |
| PL (1) | PL349025A1 (no) |
| PT (1) | PT1147095E (no) |
| SK (1) | SK10422001A3 (no) |
| TR (1) | TR200102131T2 (no) |
| WO (1) | WO2000044730A1 (no) |
| ZA (1) | ZA200104321B (no) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
| US7488754B2 (en) | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
| BR0313459A (pt) * | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
| US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
| US20040234916A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| ES2349940T3 (es) | 2004-07-21 | 2011-01-13 | Merck Serono Sa | DERIVADOS DE OCTAHIDROPIRROLO[2,3,c]PIRIDINA Y USO FARMACÉUTICO DE LOS MISMOS. |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| EP2041181B1 (en) * | 2006-06-08 | 2011-05-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Specific protease inhibitors and their use in cancer therapy |
| US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| FR2950056B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2950057B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| DK2597084T3 (en) | 2010-07-08 | 2016-08-15 | Kaken Pharma Co Ltd | N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME |
| KR101836547B1 (ko) * | 2010-09-17 | 2018-04-19 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | 혈소판의 기능을 유지하기 위한 조성물 |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
| EP4031160A4 (en) * | 2019-09-19 | 2023-10-11 | New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery | STABILIZED C-FMS INTRACELLULAR FRAGMENTS (FICD) PROMOTE OSTEOCLAST DIFFERENTIATION AND ARTHRITIC BONE EROSION |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| DK0821671T3 (da) * | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| DK0861236T4 (da) * | 1995-11-13 | 2006-12-18 | Sanofi Aventis Deutschland | Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer |
| US6153757A (en) * | 1995-12-08 | 2000-11-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors and intermediates useful for their preparation |
| US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| KR20000035918A (ko) * | 1996-08-28 | 2000-06-26 | 데이비드 엠 모이어 | 1,3-디헤테로시클릭 메탈로프로테아제 저해제 |
| CN1228772A (zh) * | 1996-08-28 | 1999-09-15 | 普罗克特和甘保尔公司 | 杂环金属蛋白酶抑制剂 |
| CA2264045A1 (en) * | 1996-08-28 | 1998-03-05 | Randall Stryker Matthews | Heterocyclic metalloprotease inhibitors |
| BR9907746A (pt) * | 1998-01-27 | 2000-10-17 | American Cyanamid Co | ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase |
-
2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en active IP Right Grant
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Application Discontinuation
-
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010101730A (ko) | 2001-11-14 |
| SK10422001A3 (sk) | 2002-09-10 |
| HUP0105302A3 (en) | 2002-09-30 |
| CZ20012637A3 (cs) | 2002-04-17 |
| IL144168A0 (en) | 2002-05-23 |
| AU767039B2 (en) | 2003-10-30 |
| CN1337952A (zh) | 2002-02-27 |
| NO20013675L (no) | 2001-09-21 |
| BR0007759A (pt) | 2001-11-13 |
| NZ511885A (en) | 2003-06-30 |
| BG105736A (en) | 2002-05-31 |
| CA2356267A1 (en) | 2000-08-03 |
| DE60012883D1 (de) | 2004-09-16 |
| AU3216000A (en) | 2000-08-18 |
| PT1147095E (pt) | 2004-12-31 |
| ID29046A (id) | 2001-07-26 |
| CN1197849C (zh) | 2005-04-20 |
| EP1147095B1 (en) | 2004-08-11 |
| ES2223470T3 (es) | 2005-03-01 |
| JP2002535392A (ja) | 2002-10-22 |
| EP1147095A1 (en) | 2001-10-24 |
| TR200102131T2 (tr) | 2001-12-21 |
| HUP0105302A2 (hu) | 2002-07-29 |
| ATE273288T1 (de) | 2004-08-15 |
| WO2000044730A1 (en) | 2000-08-03 |
| ZA200104321B (en) | 2002-08-26 |
| PL349025A1 (en) | 2002-07-01 |
| EA200100809A1 (ru) | 2002-02-28 |
| DE60012883T2 (de) | 2005-08-25 |
| AR022423A1 (es) | 2002-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200000720A (et) | Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I) | |
| NO20013675D0 (no) | 2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer | |
| DK1244647T3 (da) | Quinzolinderivater som VIGF-inhibitorer | |
| NO20002217D0 (no) | Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler | |
| DK2253620T3 (da) | Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer | |
| DK1036062T3 (da) | Hydroxamsyrederivater som matrix metalloprotease (MMP) inhibitorer | |
| DK1114032T3 (da) | 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer | |
| DK1460066T3 (da) | Piperazinforbindelse som tachykinin-inhibitorer | |
| NO20015065D0 (no) | Pyrazolobenzodiazepiner som CDK2-inhibitorer | |
| EE200000717A (et) | Uus 3-arüül-2-hüdroksüpropaanhappe derivaat III | |
| DK1210326T3 (da) | Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer | |
| DE60043730D1 (de) | Arylsulfonamid-substituierte hydroxamsäure-derivate | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| NO991994L (no) | Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriksmetalloproteaseinhibitorer | |
| NO20013853D0 (no) | Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer | |
| ATE309220T1 (de) | Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate | |
| NO20003828D0 (no) | 2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer | |
| DK1147080T3 (da) | Alkynylholdige hydroxamsyreforbindelser som TACE-inhibitorer | |
| DK1047665T3 (da) | Matrix metalloprotease inhibitorer | |
| PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
| DK1487802T3 (da) | 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer | |
| DK1147095T3 (da) | 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepin-3-hydroxamsyrer som matrixmetalloproteinaseinhibitorer | |
| IT1311642B1 (it) | Struttura di calzatura, |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |